| References |
1. Villalona-Calero MA, Petit T, Kuhn J, Cobb P, Kraynak M, Eckhardt SG, Drengler R, Simmons C, Santabarbara P, Von Hoff DD, Rowinsky EK. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies. Clin Cancer Res. 1999 Nov;5(11):3369-78. PubMed PMID: 10589747. 2. Dorr RT, Bellamy W, Liddil JD, Baker A, Bair KW. Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des. 1998 Oct;13(7):825-35. PubMed PMID: 9807165. 3. New P, Vokes E, Rogers L, Bazan C, Hohneker J, Eble M, Vilk P. Long-term response to crisnatol mesylate in patients with glioma. Invest New Drugs. 1997;15(4):343-52. PubMed PMID: 9547677. 4. Bailey H, Kohler P, Tuttle R, Carbone PP, Hohneker JA, Clendeninn NJ, Wilding G. Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days. Invest New Drugs. 1992 Nov;10(4):279-87. PubMed PMID: 1487401. |
